Skip to main content
Account

Peer review reports

From: Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling

Original Submission
4 Oct 2022 Submitted Original manuscript
4 Nov 2022 Reviewed Reviewer Report
5 Nov 2022 Reviewed Reviewer Report - Yingli Wu
12 Jan 2023 Author responded Author comments - Babu Gajendran
Resubmission - Version 2
12 Jan 2023 Submitted Manuscript version 2
17 Jan 2023 Author responded Author comments - Babu Gajendran
Resubmission - Version 3
17 Jan 2023 Submitted Manuscript version 3
26 Jan 2023 Author responded Author comments - Babu Gajendran
Resubmission - Version 4
26 Jan 2023 Submitted Manuscript version 4
27 Jan 2023 Author responded Author comments - Babu Gajendran
Resubmission - Version 5
27 Jan 2023 Submitted Manuscript version 5
11 Feb 2023 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
15 Mar 2023 Editorially accepted
4 Apr 2023 Article published 10.1186/s12885-023-10742-4

Learn about peer review

Back to article page

Navigation